GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

about

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Item

http://www.wikidata.org/entity/Q49168895

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@en

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@nl

type

Item

label

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@en

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@nl

prefLabel

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@en

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@nl

P1476

GA101 P329GLALA, a variant of ...... letion and antitumor activity.

@en

P2093

Christian Klein

http://www.w3.org/2001/XMLSchema#string

Claudia Ferrara

http://www.w3.org/2001/XMLSchema#string

Ekkehard Mössner

http://www.w3.org/2001/XMLSchema#string

Erwin van Puijenbroek

http://www.w3.org/2001/XMLSchema#string

Frank Herting

http://www.w3.org/2001/XMLSchema#string

Gunter Muth

http://www.w3.org/2001/XMLSchema#string

Kevin Brady

http://www.w3.org/2001/XMLSchema#string

Marina Bacac

http://www.w3.org/2001/XMLSchema#string

Pablo Umana

http://www.w3.org/2001/XMLSchema#string

Sabine Lang

http://www.w3.org/2001/XMLSchema#string

P2860

Obinutuzumab in hematologic malignancies: lessons learned to date

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

P304

e78-e81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.178996

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29079598

http://www.w3.org/2001/XMLSchema#string

P932

5792291

http://www.w3.org/2001/XMLSchema#string